Cancer Immunotherapy
RiboPro LNPs have been used for delivery of mRNA cancer vaccine candidates designed to enhance antigen-specific T-cell responses. In preclinical studies, LNP-formulated mRNA constructs generated strong IFNγ responses and were associated with reduced tumour growth.
The data illustrate an example of the delivery of HPV E7-OligoDOM™ mRNA using the RiboPro LNP platform. In a prophylactic TC-1 tumour model, mice were immunized prior to tumour challenge (A). Analysis of splenocytes showed strong antigen-specific IFNγ responses following vaccination, indicating effective activation of T cells against the tumour-associated antigen (B). Importantly, these enhanced immune responses translated into reduced tumour growth compared with control groups, with complete tumour growth suppression observed in the 2 µg HPV E7-OligoDOM™ treatment group (C).
These results demonstrate the ability of the RiboPro LNP platform to efficiently deliver mRNA cancer vaccine candidates and support the generation of potent anti-tumour immune responses.
Further details on the experimental setup and results can be found in the full study.